Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
282.20 | 1,479 Cr | 44.16 | 6.42 | 0.00 | 13.86 | 14.74 | 8.53 | ||
1194.00 | 1,124 Cr | 17.59 | 3.77 | 0.30 | 16.47 | 21.74 | 17.06 | ||
538.40 | 1,044 Cr | 21.47 | 10.31 | 0.00 | 43.51 | 58.07 | 27.58 | ||
78.20 | 886 Cr | 25.06 | 5.95 | 0.00 | 55.85 | 55.95 | 21.30 | ||
269.00 | 881 Cr | 32.89 | 1.29 | 0.00 | -0.30 | -4.66 | 2.89 | ||
248.20 | 622 Cr | 23.02 | 4.50 | 0.00 | 18.69 | 20.84 | 10.52 | ||
248.25 | 268 Cr | 42.73 | 4.28 | 0.00 | 13.28 | 18.53 | 9.99 | ||
| Median: 7 Co. | — | 269.00 | 886 Cr | 25.06 | 4.50 | 0.00 | 16.47 | 20.84 | 10.52 |
Sastasundar Ventures Ltd (SASTASUNDR) is currently trading at 281.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
SastaSundar Ventures Limited (proposed Health X Platform Limited) operates an integrated digital healthcare platform combining pharmaceutical distribution (Retailer Shakti), a B2C pharmacy and wellness app (SastaSundar), diagnostics enablement, and franchise-led last-mile delivery via HealthBuddy. The company holds controlling interest in SastaSundar HealthBuddy Limited and aggregates digital enablement, automated fulfilment centres and retailer SaaS to serve consumers and 62,000+ pharmacies nationwide. In Q3 FY26 SastaSundar reported consolidated healthcare operations revenue of ₹341.3 crore (total revenue ₹359.4 crore), up 22% year-on-year, with gross profit rising 55% and a gross margin of 7.6%; EBITDA loss narrowed to ₹14.8 crore and nine‑month PAT turned positive at ₹11.5 crore, driven materially by higher other income and operating efficiency improvements in procurement and fulfilment automation. The company is aggressively investing in AI and platform monetization—announcing AI integration across counselling, operations and personalized recommendations, a Retail Air SaaS for retailers, and an AI studio budget—while launching the JITO private generic brand to capture value-accretive margin expansion; these initiatives are designed to shift revenue mix, increase gross margins and monetize proprietary data and digital properties. Sastasundar emphasizes capital efficiency: management reports total capital raised of ₹352 crore and discloses a combined treasury of roughly ₹500 crore across group entities (about ₹403 crore in SastaSundar HealthBuddy Limited), consolidated borrowings near zero, and a compact working-capital profile; this liquidity is positioned to fund ₹100+ crore planned platform investments while preserving optionality for buybacks or corporate restructuring.
Over the past 52 weeks, Sastasundar Ventures Ltd has traded between a low of ₹230.00 and a high of ₹375.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sastasundar Ventures Ltd has a market capitalization of approximately 880.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sastasundar Ventures Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 880.83 Cr, Sastasundar Ventures Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sastasundar Ventures Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sastasundar Ventures Ltd is 33.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
6
Neutral
3
Bullish
5
Bearish
17
Neutral
3
Bullish
26
Bearish
11
Neutral
0
Bullish
21
SastaSundar Ventures Limited (proposed Health X Platform Limited) operates an integrated digital healthcare platform combining pharmaceutical distribution (Retailer Shakti), a B2C pharmacy and wellness app (SastaSundar), diagnostics enablement, and franchise-led last-mile delivery via HealthBuddy. The company holds controlling interest in SastaSundar HealthBuddy Limited and aggregates digital enablement, automated fulfilment centres and retailer SaaS to serve consumers and 62,000+ pharmacies nationwide.
In Q3 FY26 SastaSundar reported consolidated healthcare operations revenue of ₹341.3 crore (total revenue ₹359.4 crore), up 22% year-on-year, with gross profit rising 55% and a gross margin of 7.6%; EBITDA loss narrowed to ₹14.8 crore and nine‑month PAT turned positive at ₹11.5 crore, driven materially by higher other income and operating efficiency improvements in procurement and fulfilment automation.
The company is aggressively investing in AI and platform monetization—announcing AI integration across counselling, operations and personalized recommendations, a Retail Air SaaS for retailers, and an AI studio budget—while launching the JITO private generic brand to capture value-accretive margin expansion; these initiatives are designed to shift revenue mix, increase gross margins and monetize proprietary data and digital properties.
Sastasundar emphasizes capital efficiency: management reports total capital raised of ₹352 crore and discloses a combined treasury of roughly ₹500 crore across group entities (about ₹403 crore in SastaSundar HealthBuddy Limited), consolidated borrowings near zero, and a compact working-capital profile; this liquidity is positioned to fund ₹100+ crore planned platform investments while preserving optionality for buybacks or corporate restructuring.
Healthcare Services
Healthcare Service Provider
881 Cr
Low Risk
33.9
56.7
0.8
1.3
375.00
230.00
Sales CAGR
Profit CAGR
ROE
ROCE
